Format

Send to

Choose Destination
Expert Opin Emerg Drugs. 2015 Mar;20(1):129-35. doi: 10.1517/14728214.2015.985204. Epub 2014 Dec 13.

Emerging drugs for celiac disease.

Author information

1
University of British Columbia, Department of Medicine (Gastroenterology) , Vancouver, BC , Canada hugfree@shaw.ca.

Abstract

INTRODUCTION:

Celiac disease is an immune-mediated gluten-dependent disorder, primarily affecting the small intestine in genetically predisposed individuals. The disorder has a very heterogeneous clinical and histopathological spectrum. Current treatment with a gluten-free diet is very effective, but the diet is difficult to maintain and remains costly.

AREAS COVERED:

Alternatives to the gluten-free diet have been proposed to either replace this current treatment, or at least, to supplement use of the gluten-free diet. Studies in the published English language literature relevant to this review were examined for this report.

EXPERT OPINION:

Most recent published double-blind, placebo-controlled clinical trials have focused on an orally administered recombinant glutenase (ALV003) showing significant but limited benefit to celiac disease patients already compliant with a gluten-free diet. Other studies have addressed other immune mechanisms that may play a role in its pathogenesis and have not been so positive. Added investigations, particularly over the long-term, in other larger and more heterogeneous populations are needed.

KEYWORDS:

celiac disease; celiac disease therapy; enzyme treatment; gluten-free diet; gluten-sensitive enteropathy; glutenase; larazotide

PMID:
25494908
DOI:
10.1517/14728214.2015.985204
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center